IRIS
TOCCHETTI, CARLO GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.686
AS - Asia 10.544
EU - Europa 7.269
SA - Sud America 1.253
Continente sconosciuto - Info sul continente non disponibili 576
AF - Africa 331
OC - Oceania 21
Totale 31.680
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.083
SG - Singapore 4.537
RU - Federazione Russa 3.037
CN - Cina 1.975
VN - Vietnam 1.801
IT - Italia 1.793
BR - Brasile 976
HK - Hong Kong 962
DE - Germania 447
FR - Francia 416
CA - Canada 355
FI - Finlandia 310
BD - Bangladesh 305
NL - Olanda 287
GB - Regno Unito 215
IN - India 182
JP - Giappone 181
UA - Ucraina 148
SE - Svezia 129
IE - Irlanda 105
AR - Argentina 98
KR - Corea 91
CI - Costa d'Avorio 88
ZA - Sudafrica 79
MX - Messico 77
PH - Filippine 68
IQ - Iraq 67
ES - Italia 58
EC - Ecuador 52
PL - Polonia 51
AT - Austria 48
CO - Colombia 46
ID - Indonesia 42
PK - Pakistan 38
TH - Thailandia 37
TR - Turchia 37
LT - Lituania 35
TW - Taiwan 35
PT - Portogallo 33
VE - Venezuela 31
JM - Giamaica 27
BE - Belgio 26
IL - Israele 26
EG - Egitto 25
CR - Costa Rica 21
KE - Kenya 20
NI - Nicaragua 20
TT - Trinidad e Tobago 20
MA - Marocco 18
BG - Bulgaria 17
DZ - Algeria 17
UZ - Uzbekistan 17
NG - Nigeria 16
NP - Nepal 15
AE - Emirati Arabi Uniti 14
CL - Cile 14
HN - Honduras 14
SK - Slovacchia (Repubblica Slovacca) 14
EE - Estonia 13
MY - Malesia 13
DO - Repubblica Dominicana 12
GT - Guatemala 12
TN - Tunisia 12
AU - Australia 11
AZ - Azerbaigian 11
PE - Perù 11
PY - Paraguay 11
JO - Giordania 10
CH - Svizzera 9
ET - Etiopia 9
GE - Georgia 9
LB - Libano 9
RO - Romania 9
SV - El Salvador 9
CZ - Repubblica Ceca 8
GR - Grecia 8
HR - Croazia 8
IR - Iran 8
SC - Seychelles 8
KZ - Kazakistan 7
PR - Porto Rico 7
BO - Bolivia 6
DK - Danimarca 6
MK - Macedonia 6
NZ - Nuova Zelanda 6
OM - Oman 6
RS - Serbia 6
SA - Arabia Saudita 6
UY - Uruguay 6
AL - Albania 5
AM - Armenia 5
BB - Barbados 5
KW - Kuwait 5
LV - Lettonia 5
PA - Panama 5
PS - Palestinian Territory 5
AO - Angola 4
CY - Cipro 4
HT - Haiti 4
SY - Repubblica araba siriana 4
Totale 31.019
Salva come PNG Salva come JPEG
Città #
Singapore 2.182
San Jose 1.750
Ashburn 1.316
Hong Kong 941
Chandler 779
Moscow 730
Council Bluffs 569
Beijing 496
Ho Chi Minh City 490
Hefei 416
Hanoi 371
Santa Clara 364
Naples 322
The Dalles 287
Los Angeles 274
Lauterbourg 250
Amsterdam 217
Millbury 187
Boston 166
New York 160
Nanjing 155
Dallas 152
Tokyo 146
Des Moines 145
Princeton 144
Buffalo 121
Munich 120
São Paulo 112
Wilmington 111
Jacksonville 109
Milan 106
Redondo Beach 106
Phoenix 94
Rome 90
Da Nang 87
Dong Ket 86
Lawrence 86
Haiphong 79
Frankfurt am Main 78
Seattle 76
Seoul 75
Helsinki 73
Napoli 70
Lappeenranta 67
Ottawa 66
Toronto 66
Orem 63
Atlanta 61
Chicago 60
Woodbridge 60
Montreal 56
Brooklyn 54
Houston 54
Nuremberg 54
Turku 54
Denver 47
London 47
North Bergen 44
Warsaw 41
Hebei 40
Nanchang 39
Mexico City 37
Falkenstein 34
San Francisco 33
Shenyang 33
Stockholm 33
Pune 32
Belo Horizonte 28
Hải Dương 28
Palermo 27
Washington 27
Bologna 26
Turin 26
Boardman 25
Can Tho 25
Charlotte 25
Johannesburg 25
Kochi 25
Rio de Janeiro 25
Chennai 24
Guangzhou 24
Biên Hòa 23
Caserta 23
Changsha 23
Dublin 23
Manchester 23
Norwalk 23
Tianjin 23
Guayaquil 21
Kingston 21
Shanghai 21
Brasília 20
Dearborn 20
Fairfield 20
Quito 20
Bogotá 19
Jiaxing 19
Managua 19
Paris 19
Salt Lake City 19
Totale 16.622
Salva come PNG Salva come JPEG
Nome #
Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice 758
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) 239
Right ventricular failure in left heart disease: from pathophysiology to clinical manifestations and prognosis 232
Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology 213
Meccanismi molecolari della cardiotossicità indotta da antracicline e radioterapia 212
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 197
Antineoplastic drug-induced cardiotoxicity: A redox perspective 193
Cardiac sympathetic dysfunction in pulmonary arterial hypertension: Lesson from left-sided heart failure 193
European Society of Cardiology Core Curriculum for Cardio-Oncology 190
Toward standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function 190
Myocardial collagen turnover in hypertrophic cardiomyopathy 179
Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production 179
Adapted recreational football Small Sided Games improves cardiac capacity, body composition and muscular fitness in patients with type 2 diabetes: results from a pilot study 179
A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases 179
The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better 174
Biomarkers in sarcopenia: A multifactorial approach. 173
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 172
Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs. Novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart 171
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 170
Dobutamine stress echocardiography in hypertrophic cardiomyopathy 168
Inflammatory, Serological and Vascular Determinants of Cardiovascular Disease in Systemic Lupus Erythematosus Patients 168
Bmi1 inhibitor PTC-209 promotes Chemically-induced Direct Cardiac Reprogramming of cardiac fibroblasts into cardiomyocytes 167
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue 167
Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: Preliminary results of a single-centre phase II study 166
Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart 166
Prevention of cardiovascular complications in elderly cancer patients 165
Nanotechnology-Based Cardiac Targeting and Direct Cardiac Reprogramming: The Betrothed 164
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology 164
Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi-Center Real-Life Study 163
Cardiotoxicity of immune checkpoint inhibitors 162
The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) 162
Mitral peak early diastolic filling velocity to deceleration time ratio as a predictor of prognosis in patients with chronic heart failure and preserved or reduced ejection fraction. 161
Abnormal glucose transport and GLUT1 cell-surface content in fibroblasts and skeletal muscle from NIDDM and obese subjects 161
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 161
An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology 158
New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management 158
Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. 157
Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients 157
Oxidative stress in anticancer therapies-related cardiac dysfunction 157
Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications 156
Management of aortic stenosis and chronic heart failure: A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC 154
Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology 153
What is the cardiac impact of chemotherapy and subsequent radiotherapy in lymphoma patients 153
Complex Roads from Genotype to Phenotype in Dilated Cardiomyopathy: Scientific update from the Working Group of Myocardial Function of the European Society of Cardiology 151
Autophagy and cancer therapy cardiotoxicity: From molecular mechanisms to therapeutic opportunities 151
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function 149
Permanent atrial fibrillation and pulmonary embolism in elderly patients without deep vein thrombosis: is there a relationship? 149
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 149
The innate immune system in chronic cardiomyopathy: A European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC 148
A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial 147
Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function 147
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology 146
Editorial: Myocardium regeneration and cardioprotection 145
The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology 145
The Influence of Fiber on Gut Microbiota: Butyrate as Molecular Player Involved in the Beneficial Interplay Between Dietary Fiber and Cardiovascular Health 144
PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus 143
Common Mechanistic Pathways in Cancer and Heart Failure 143
Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC 142
Acute heart failure: mechanisms and pre-clinical models-a Scientific Statement of the ESC Working Group on Myocardial Function 142
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. 142
Severe Aortic Valve Regurgitation in Relapsing Polychondritis 142
Pulmonary Hypertension Phenotypes in Systemic Sclerosis: The Right Diagnosis for the Right Treatment 142
EARLY IDENTIFICATION OF LEFT VENTRICULAR DYSFUNCTION WITH SPECKLE TRACKING ECHOCARDIOGRAPHY IN ANTINEOPLASTIC THERAPY-INDUCED CARDIOTOXICITY 141
Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs 140
Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth 140
Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology 139
Mildly Elevated Pulmonary Hypertension: Gray Zone or Already a Disease? 139
Myocardial collagen turnover in hypertrophic cardiomyopathy 139
Targeting fibrosis in the failing heart with nanoparticles. 138
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 138
Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC 137
Physical vs. multidimensional frailty in older adults with and without heart failure 137
Low-intensity pulsed ultrasound (LIPUS) in heart failure with preserved ejection fraction (HFpEF): lupus in fabula? 137
Epidemiology, Pathophysiology, Diagnosis and Management of Chronic Right-Sided Heart Failure and Tricuspid Regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC 136
Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. 136
Prognostic Significance of Left Atrial Volume Dilatation in Patients with Hypertrophic Cardiomyopathy 136
A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: An opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology 136
Cancer diagnosis in patients with heart failure: Epidemiology, clinical implications and gaps in knowledge 136
Cardiovascular events and treatment of children with high risk medulloblastoma 136
Hemodynamic effects of isometric exercise in hypertrophic cardiomyopathy: comparison with normal subjects 135
Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure 135
Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis 134
Redox imbalances in ageing and metabolic alterations: Implications in cancer and cardiac diseases. An overview from the working group of cardiotoxicity and cardioprotection of the Italian society of cardiology (SIC) 133
Priorities in Cardio-Oncology Basic and Translational Science 132
Mitochondrial targets in ischaemic heart disease and heart failure, and their potential for a more efficient clinical translation. A scientific statement of the ESC Working Group on Cellular Biology of the Heart and the ESC Working Group on Myocardial Function 132
Nitroxyl: A positive inotrope enhancing SR CA(2+) cycling in isolated myocytes 131
Novel Therapeutic Approaches and Targets for the Treatment of Cardiovascular and Immunological Diseases 131
The continuous heart failure spectrum: moving beyond an ejection fraction classification 131
Reciprocal organ interactions during heart failure-a position paper from the ESC working group on myocardial function 130
Awareness, access, and adoption of natriuretic peptides for diagnosis of heart failure 129
Non-coding RNAs - Update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart 129
Circulating miR-10b-5p, miR-193a-3p, and miR-1-3p Are Deregulated in Patients with Heart Failure and Correlate with Hormonal Deficiencies 128
Editorial: Novel Therapeutic Strategies for the Treatment of Chronic Diseases 128
Education and Certification on Heart Failure of the Heart Failure Association of the European Society of Cardiology 128
Janus, or the inevitable battle between too much and too little oxygen 127
The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology 127
'Circulating' RNA-based therapies in Cardio-Oncology 126
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors 126
How to facilitate seamless translation from basic concepts to new heart failure drugs. A scientific statement of the Heart Failure Association of the ESC 125
The broad spectrum of cardiotoxicities from immunotherapies 125
Totale 15.891
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.323
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 105.323
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.061 0 0 0 0 30 32 42 62 101 100 190 504
2022/20232.192 251 122 84 176 273 209 58 258 381 240 105 35
2023/20241.527 47 190 230 115 89 216 72 184 29 48 213 94
2024/20257.219 352 438 40 62 141 443 701 508 609 764 2.481 680
2025/202614.241 1.492 1.079 1.421 1.211 2.267 580 1.782 872 1.563 1.001 473 500
2026/20273.315 364 511 741 1.605 94 0 0 0 0 0 0 0
Totale 31.680